|
|
Volumn 93, Issue 3, 2001, Pages 175-176
|
|
FDA panel recommends two new cancer drugs for approval
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
AROMATASE;
AROMATASE INHIBITOR;
CD52 ANTIGEN;
FLUDARABINE;
HISTAMINE;
HORMONE RECEPTOR;
HUMAN MONOCLONAL ANTIBODY;
INTERLEUKIN 2;
LETROZOLE;
MAXAMINE;
NEW DRUG;
TAMOXIFEN;
UNCLASSIFIED DRUG;
ADVANCED CANCER;
BLOOD TOXICITY;
BREAST CANCER;
CANCER SURVIVAL;
CARDIOVASCULAR DISEASE;
CEREBROVASCULAR DISEASE;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG MECHANISM;
DRUG RESPONSE;
ENDOMETRIUM CANCER;
EYE TOXICITY;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
FRACTURE;
HUMAN;
INFECTION;
MELANOMA;
NOTE;
POSTMENOPAUSE;
PRIORITY JOURNAL;
THROMBOEMBOLISM;
TREATMENT FAILURE;
|
|
EID: 0035819523
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/93.3.175 Document Type: Note |
|
Times cited : (13)
|
|
References (0)
|